Log in

OTCMKTS:PVOTFPivot Pharmaceuticals Stock Price, Forecast & News

-0.15 (-8.57 %)
(As of 07/3/2020 04:00 PM ET)
Today's Range
Now: $1.60
50-Day Range
MA: $0.22
52-Week Range
Now: $1.60
Volume40,344 shs
Average VolumeN/A
Market Capitalization$274.26 million
P/E RatioN/A
Dividend YieldN/A
Pivot Pharmaceuticals, Inc. is a development stage biopharmaceutical company. It is engaged in the development and commercialization of therapeutic pharmaceutical products, with a strategic emphasis on the innovation of new therapeutic uses for existing drugs. The company was founded on June 10, 2002 and is headquartered in Vancouver, Canada.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 0.0Community Rank: 2.6Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

0.52 out of 5 stars

Industry, Sector and Symbol

Industry Pharmaceutical preparations



Sales & Book Value

Annual SalesN/A
Book Value$0.01 per share


Net Income$-14,780,000.00


Market Cap$274.26 million
Next Earnings DateN/A
OptionableNot Optionable

Receive PVOTF News and Ratings via Email

Sign-up to receive the latest news and ratings for PVOTF and its competitors with MarketBeat's FREE daily newsletter.

Pivot Pharmaceuticals (OTCMKTS:PVOTF) Frequently Asked Questions

How has Pivot Pharmaceuticals' stock been impacted by COVID-19 (Coronavirus)?

Pivot Pharmaceuticals' stock was trading at $0.0714 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, PVOTF shares have increased by 2,140.9% and is now trading at $1.60. View which stocks have been most impacted by Coronavirus.

How were Pivot Pharmaceuticals' earnings last quarter?

Pivot Pharmaceuticals Inc (OTCMKTS:PVOTF) released its earnings results on Monday, June, 1st. The company reported ($0.05) earnings per share (EPS) for the quarter. View Pivot Pharmaceuticals' earnings history.

Has Pivot Pharmaceuticals been receiving favorable news coverage?

News articles about PVOTF stock have been trending negative recently, InfoTrie reports. The research firm rates the sentiment of press coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of companies on a scale of negative five to five, with scores closest to five being the most favorable. Pivot Pharmaceuticals earned a media sentiment score of -2.2 on InfoTrie's scale. They also gave media stories about the company a news buzz of 5.0 out of 10, indicating that recent press coverage is somewhat likely to have an impact on the company's share price in the near term. View the latest news about Pivot Pharmaceuticals.

Who are some of Pivot Pharmaceuticals' key competitors?

Who are Pivot Pharmaceuticals' key executives?

Pivot Pharmaceuticals' management team includes the following people:
  • Joseph Borovsky, Chairman & Executive Vice President-Technology
  • Patrick Charles Frankham, President, CEO, Director & VP-Business Development
  • Moira Ong, Chief Financial Officer
  • Wolfgang Renz, Director & Chief Medical Officer

What is Pivot Pharmaceuticals' stock symbol?

Pivot Pharmaceuticals trades on the OTCMKTS under the ticker symbol "PVOTF."

How do I buy shares of Pivot Pharmaceuticals?

Shares of PVOTF can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Pivot Pharmaceuticals' stock price today?

One share of PVOTF stock can currently be purchased for approximately $1.60.

How big of a company is Pivot Pharmaceuticals?

Pivot Pharmaceuticals has a market capitalization of $274.26 million.

What is Pivot Pharmaceuticals' official website?

The official website for Pivot Pharmaceuticals is pivotpharma.com.

How can I contact Pivot Pharmaceuticals?

Pivot Pharmaceuticals' mailing address is 1275 WEST 6TH AVENUE, VANCOUVER A1, V6H 1A6. The company can be reached via phone at 604-805-7783.

This page was last updated on 7/5/2020 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools:

  • Best-in-Class Portfolio Monitoring

    View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.

  • Stock Ideas and Recommendations

    Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.

  • Advanced Stock Screeners and Research Tools

    Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.